Reviewer’s report

Title: Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multi-center, active-control Phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

Version: 3 Date: 5 March 2013

Reviewer: Caterina Fontanella

Reviewer’s report:

Minor Essential Revisions

1. There are some missing spaces, i.e. background, page 5, line 18 “…lipegfilgrastimversus pegfilgrastim were…”

2. Results, patient disposition, page 13: “The PK substudy population was composed of 41 patients (lipegfilgrastim n = 24 and pegfilgrastim n = 17) from the ITT population” but figure 1 shows 17 patients in both treatment arms.

Discretionary Revisions


2. Materials and methods, endpoints, page 8, lines 21-22: “…severe neutropenia (grade 4, ANC <0.5 × 10⁹/L)…” Authors should consider specifying the NCI CTCAE version.

3. Table 1 is not so easy to read, I would suggest to simplify it.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.
Dr. Caterina Fontanella